Publication:
The influence of systemic inflammation response index on survival outcomes of limited-stage small-cell lung cancer patients treated with concurrent chemoradiotherapy

dc.contributor.coauthorKüçük, Ahmet
dc.contributor.coauthorÖzkan, Emine Elif
dc.contributor.coauthorÖztep, Şükran Eskici
dc.contributor.coauthorMertsoylu, Hüseyin
dc.contributor.coauthorPehlivan, Berrin
dc.contributor.coauthorTopkan, Erkan
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T11:36:24Z
dc.date.issued2020
dc.description.abstractBackground: recent studies have indicated that the systemic inflammation response index (SIRI) can efficiently predict survival outcomes in various tumor types. Thusly, in absence of comparable investigations in limited-stage small-cell lung cancers (LS-SCLCs), we aimed to retrospectively evaluate the prognostic utility of SIRI in LS-SCLC patients treated with concurrent chemoradiotherapy (CRT). Patients and methods: present multi-institutional retrospective analysis incorporated LS-SCLC patients treated with CRT at three academic radiation oncology centers between January 2007 and December 2018. The SIRI was calculated by using the peripheral blood neutrophil (N), monocyte (M), and lymphocyte (L) counts acquired in the last <= 7 days before the commencement of the CRT: SIRI = N x M/L. Accessibility of pretreatment SIRI cutoff that may stratify the study population into two gatherings with distinctive overall survival (OS) results was evaluated by utilizing the receiver operating characteristic (ROC) curve analysis. Primary objective was the association between the SIRI values and the OS results. Results: search for the availability of an ideal SIRI cutoff that may stratify the entire patients' population into two particular groups with distinctive OS outcomes identified the 1.93 value (area under the curve (AUC): 72.9%; sensitivity: 74.6%; specificity: 70.1%): Group 1: SIRI <1.93 (N = 71) and Group 2: SIRI >= 1.93 (N = 110), respectively. At a median follow-up of 17.9 (95% CI: 13.2-22.6) months, 47 (26.0%) patients were still alive (47.9% for SIRI p<0.001). Kaplan-Meier comparisons between the two SIRI groups showed that the SIRI <1.93 cohort had significantly longer median OS (40.5 versus 14.2 months; p<0.001) than the SIRI >= 1.93 cohort. Similarly, the 3- (54% versus 12.6%) and 5-year (33% versus 9.9%) OS rates were also numerically superior in the SIRI Conclusions: the results of this retrospective multi-institutional cohort analysis suggested that a pre-CRT SIRI was a strong and independent prognostic biomarker that reliably stratified LS-SCLC patients into two cohorts with significantly different OS outcomes.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume2020
dc.identifier.doi10.1155/2020/8832145
dc.identifier.eissn1687-8469
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR02597
dc.identifier.issn1687-8450
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85098586265
dc.identifier.urihttps://hdl.handle.net/20.500.14288/57
dc.identifier.wos603524100001
dc.keywordsNeutrophil-lymphocyte Ratio
dc.keywordsPrognostic-factors
dc.keywordsLaboratory parameters
dc.keywordsPredicts prognosis
dc.keywordsSIRI
dc.keywordsCarcinoma
dc.keywordsScore
dc.keywordsRadiotherapy
dc.keywordsCisplatin
dc.language.isoeng
dc.publisherHindawi
dc.relation.grantnoNA
dc.relation.ispartofJournal of Oncology
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/9236
dc.subjectMedicine
dc.subjectOncology
dc.titleThe influence of systemic inflammation response index on survival outcomes of limited-stage small-cell lung cancer patients treated with concurrent chemoradiotherapy
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
9236.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format